Ignite Creation Date:
2024-05-06 @ 1:04 PM
Last Modification Date:
2024-10-26 @ 1:08 PM
Study NCT ID:
NCT03924375
Status:
COMPLETED
Last Update Posted:
2020-07-27
First Post:
2019-04-20
Brief Title:
Serum Pepsinogen After H Pylori Eradication
Sponsor:
Soonchunhyang University Hospital
Organization:
Soonchunhyang University Hospital
Study Overview
Official Title:
Serum Pepsinogen After Helicobacter Pylori Eradication for the Gastric Cancer Prevention
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis Current guidelines recommend the H pylori test-and-treat strategy for the purpose of primary and secondary gastric cancer prevention Considering the point of no return theory however H pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development Recently the secretory ability of the stomach can be measured using the serum pepsinogen PG assay
Detailed Description:
This study aimed to evaluate the change of serum PGs after H pylori eradication success and identify the optimal timing of eradication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None